Overall, the reportable complaints rate remains low (< 0.3% yearly) and the PMCF activities conducted do not reveal any new safety or performance concerns during real-world commercial use.Therefore, the clinical data generated and held by the manufacturer for the EPIQ System support the fulfillment of the relevant General Safety and Performance Requirements.